Myths vs facts: Pharmakogenetik Medicheck and menopause

Regarding myths vs facts about pharmacogenetics (Medicheck) and menopause, the provided context contains no direct information on this specific test or topic. Generally, pharmacogenetics can analyze genetic variants in drug-metabolizing enzymes like CYP2D6 or CYP3A4, which affect how drugs such as tamoxifen or certain antidepressants are processed – medications often used during menopause. A common myth is that a DNA test can precisely predict the optimal drug and dose. The fact is that effect sizes are modest, and interactions with hormonal changes, lifestyle, and other medications are complex. The MyBody-X Pharmakogenetik Medicheck is not mentioned in the context, so it is unclear whether it exists or which markers it includes. Without clinical validation and physician oversight, such a test may be misleading. The evidence level is therefore rated as unclear. Safety note: Any medication adjustments during menopause should be guided by a healthcare professional, not solely by a genetic test.